The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.
Disease-modifying therapy
Immune reconstitution therapy
Multiple sclerosis
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
25
10
2022
accepted:
29
11
2022
medline:
24
12
2022
pubmed:
24
12
2022
entrez:
23
12
2022
Statut:
ppublish
Résumé
The treatment strategy in relapsing multiple sclerosis (RMS) is a complex decision requiring individualization of treatment sequences to maximize clinical outcomes. Current local and international guidelines do not provide specific recommendation on the use of immune reconstitution therapy (IRT) as alternative to continuous immunosuppression in the management of RMS. The objective of the program was to provide consensus-based expert opinion on the optimal use of IRT in the management of RMS. A Delphi method was performed from May 2022 to July 2022. Nineteen clinical assertions were developed by a scientific committee and sent to 14 French clinical experts in MS alongside published literature. Two consecutive reproducible anonymous votes were conducted. Consensus on recommendations was achieved when more than 75% of the respondents agreed or disagreed with the clinical assertions. After the second round, consensus was achieved amongst 16 out of 19 propositions: 13 clinical assertions had a 100% consensus, 3 clinical assertions a consensus above 75% and 3 without consensus. Expert-agreed consensus is provided on topics related to the benefit of the early use of IRT from immunological and clinical perspectives, profiles of patients who may benefit most from the IRT strategy (e.g. patients with family planning, patient preference and lifestyle requirements). These French expert consensuses provide up-to-date relevant guidance on the use of IRT in clinical practice. The current program reflects status of knowledge in 2022 and should be updated in timely manner when further clinical data in IRT become available.
Identifiants
pubmed: 36564664
doi: 10.1007/s40120-022-00430-z
pii: 10.1007/s40120-022-00430-z
pmc: PMC10043116
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
351-369Informations de copyright
© 2022. The Author(s).
Références
Clark D, Jones S. Multiple sclerosis: disease-modifying therapies. Pharm J. https://pharmaceutical-journal.com/article/ld/multiple-sclerosis-disease-modifying-therapies . Accessed Aug 2022.
Giovannoni G. Personalized medicine in multiple sclerosis. Neurodegener Dis Manag. 2017;7:13–7.
pubmed: 29143582
doi: 10.2217/nmt-2017-0035
AlSharoqi IA, Aljumah M, Bohlega S, et al. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? A narrative review. Neurol Ther. 2020;9:55–66.
pubmed: 32297127
pmcid: 7229056
doi: 10.1007/s40120-020-00187-3
Alroughani R, Inshasi JS, Deleu D, et al. An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion. Neurol Ther. 2019;8:13–23.
pubmed: 30875021
pmcid: 6534637
doi: 10.1007/s40120-019-0129-0
Casanova B, Quintanilla-Bordás C, Gascón F. Escalation vs. early intense therapy in multiple sclerosis. J Pers Med. 2022;12:119.
pubmed: 35055434
pmcid: 8778390
doi: 10.3390/jpm12010119
Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269(3):1670–7.
pubmed: 34626224
doi: 10.1007/s00415-021-10836-8
Simonsen CS, Flemmen HØ, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12: 693017.
pubmed: 34220694
pmcid: 8248666
doi: 10.3389/fneur.2021.693017
Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;28(12):1756286419836913.
Pfeuffer S, Rolfes L, Hackert J, et al. Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres. Mult Scler. 2022;28:257–68.
pubmed: 33975489
doi: 10.1177/13524585211012227
Bose G, Rush C, Atkins HL, Freedman MS. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. Mult Scler Relat Disord. 2021;52: 102945.
pubmed: 33901969
doi: 10.1016/j.msard.2021.102945
Rauma I, Viitala M, Kuusisto H, et al. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Mult Scler Relat Disord. 2022;61: 103755.
pubmed: 35483129
doi: 10.1016/j.msard.2022.103755
Patti F, Visconti A, Capacchione A, Roy S, Trojano M, CLARINET-MS Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020;13:1756286420922685.
pubmed: 32587633
pmcid: 7294475
doi: 10.1177/1756286420922685
Frau J, Coghe G, Lorefice L, Fenu G, Musu L, Cocco E. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. 2019;266:1405–11.
pubmed: 30863891
doi: 10.1007/s00415-019-09272-6
Coles AJ, Arnold DL, Bass AD, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther Adv Neurol Disord. 2021;14:1756286420982134.
pubmed: 34035833
pmcid: 8072102
doi: 10.1177/1756286420982134
Steingo B, Al Malik Y, Bass AD, et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020;267:3343–53.
pubmed: 32583052
pmcid: 7578137
doi: 10.1007/s00415-020-09983-1
Russo CV, Saccà F, Frau J, et al. A real-world study of alemtuzumab in a cohort of Italian patients. Eur J Neurol. 2022;29(1):257–66.
pubmed: 34558755
doi: 10.1111/ene.15121
Khalili E, Venning B, Boggild M, Broadley SA. Real world experience of treating multiple sclerosis with alemtuzumab. The Australian & New Zealand Association of Neurologists (ANZAN) meeting, May 29th–June 1st, 2018 (Abstract 082). https://jnnp.bmj.com/content/89/6/A33.2 . Accessed Aug 2022.
Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003;41:376–82.
pubmed: 12581103
doi: 10.1046/j.1365-2648.2003.02537.x
Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol. 2005;5:37.
pubmed: 16321161
pmcid: 1318466
doi: 10.1186/1471-2288-5-37
Kwong JS, Chen H, Sun X. Development of evidence-based recommendations: implications for preparing expert consensus statements. Chin Med J (Engl). 2016;129:2998–3000.
pubmed: 27958233
doi: 10.4103/0366-6999.195475
Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67:401–9.
pubmed: 24581294
doi: 10.1016/j.jclinepi.2013.12.002
Simoens S. Using the Delphi technique in economic evaluation: time to revisit the oracle? J Clin Pharm Ther. 2006;31:519–22.
pubmed: 17176357
doi: 10.1111/j.1365-2710.2006.00780.x
Avella JR. Delphi panels: research design, procedures, advantages, and challenges. Int J Dr Stud. 2016;11:305–21.
Mohammadi R, Aryan A, Omrani MD, Ghaderian SMH, Fazeli Z. Autologous hematopoietic stem cell transplantation (AHSCT): an evolving treatment avenue in multiple sclerosis. Biologics. 2021;15:53–9.
pubmed: 33688164
pmcid: 7936693
Sharrack B, Saccardi R, Alexander T, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55:283–306.
pubmed: 31558790
doi: 10.1038/s41409-019-0684-0
Wawrzyniak S, Rzepiński Ł. Is there a new place for mitoxantrone in the treatment of multiple sclerosis? Neurol Neurochir Pol. 2020;54:54–61.
pubmed: 31922582
doi: 10.5603/PJNNS.a2019.0069
Kingwell E, Koch M, Leung B, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010;74:1822–6.
pubmed: 20427751
pmcid: 2882218
doi: 10.1212/WNL.0b013e3181e0f7e6
Smets I, Wokke B, Smolders J. Should anti-CD20 be used as an immune reconstitution therapy? Mult Scler. 2022;13524585221109386.
Sellner J, Rommer PS. Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: a systematic review. Autoimmun Rev. 2020;19: 102492.
pubmed: 32062028
doi: 10.1016/j.autrev.2020.102492
Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011;76:1996–2001.
pubmed: 21646626
doi: 10.1212/WNL.0b013e31821e559d
Freedman MS, Rush CA. Severe, highly active, or aggressive multiple sclerosis. Continuum (Minneap Minn). 2016;22:761–84.
pubmed: 27261681
Menon S, Zhu F, Shirani A, Oger J, Freedman MS, Tremlett H. Disability progression in aggressive multiple sclerosis. Mult Scler. 2017;23:456–63.
pubmed: 27325603
doi: 10.1177/1352458516653273
Spelman T, Freilich J, Anell B, Wong SL, Hillert J. Patients with high-disease-activity relapsing-remitting multiple sclerosis in real-world clinical practice: a population-based study in Sweden. Clin Ther. 2020;42:240–50.
pubmed: 31899001
doi: 10.1016/j.clinthera.2019.11.018
Alroughani R, Inshasi J, Al-Asmi A, et al. Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity. Postgrad Med. 2020;132:368–76. https://doi.org/10.1080/00325481.2020.1734394 .
doi: 10.1080/00325481.2020.1734394
pubmed: 32089038
Sørensen PS, Centonze D, Giovannoni G, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1756286420935019.
pubmed: 32636933
pmcid: 7318823
doi: 10.1177/1756286420935019
Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8:a028936.
pubmed: 29358320
pmcid: 5830904
doi: 10.1101/cshperspect.a028936
Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2019;9:3116.
pubmed: 30687321
pmcid: 6335289
doi: 10.3389/fimmu.2018.03116
Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19(4 Multiple Sclerosis):901–21.
pubmed: 23917093
Gallo P, Van Wijmeersch B, ParadigMS Group. Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Eur J Neurol. 2015;22(Suppl 2):14–21.
pubmed: 26374509
doi: 10.1111/ene.12799
Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18:27.
pubmed: 29523094
pmcid: 5845207
doi: 10.1186/s12883-018-1026-3
Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the “real MS.” Ther Adv Neurol Disord. 2022;15:17562864211066752.
pubmed: 35096143
pmcid: 8793117
doi: 10.1177/17562864211066751
Rojas JI, Patrucco L, Alonso R, et al. Effectiveness and safety of early high-efficacy versus escalation therapy in relapsing-remitting multiple sclerosis in Argentina. Clin Neuropharmacol. 2022;45:45–51.
pubmed: 35579483
doi: 10.1097/WNF.0000000000000503
Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78:1197–204.
pubmed: 34398221
doi: 10.1001/jamaneurol.2021.2738
Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175–87.
pubmed: 30644981
pmcid: 6439772
doi: 10.1001/jama.2018.20588
Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536–41.
pubmed: 30776055
pmcid: 6515582
doi: 10.1001/jamaneurol.2018.4905
Ontaneda D, Tallantyre EC, Raza PC, et al. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: the DELIVER-MS study protocol. Contemp Clin Trials. 2020;95: 106009.
pubmed: 32320842
doi: 10.1016/j.cct.2020.106009
DELIVER MS trial website. https://deliver-ms.com/ . Accessed Sep 2022.
Ziemssen T, Hoffmann F, Richter S, Engelmann U, White R. Alemtuzumab in a large real-life cohort: interim baseline data of the TREAT-MS study. Front Neurol. 2021;12: 620758.
pubmed: 34421780
pmcid: 8375470
doi: 10.3389/fneur.2021.620758
Rival M, Galoppin M, Thouvenot E. Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol. 2022;13: 866092.
pubmed: 35572543
pmcid: 9094445
doi: 10.3389/fimmu.2022.866092
Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273–9.
pubmed: 26101071
doi: 10.1136/practneurol-2015-001139
Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C. Efficacy classification of modern therapies in multiple sclerosis. Future Med. 2021;10:495–507.
Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648.
pubmed: 34422112
pmcid: 8377320
doi: 10.1177/17562864211039648
Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.
pubmed: 29353550
doi: 10.1177/1352458517751049
Giovannoni G, Mathews J. Cladribine tablets for relapsing-remitting multiple sclerosis: a clinician’s review. Neurol Ther. 2022;11:571–95.
pubmed: 35318617
pmcid: 8940595
doi: 10.1007/s40120-022-00339-7
Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168–74.
pubmed: 30885375
doi: 10.1016/j.msard.2019.01.038
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.
pubmed: 28626781
pmcid: 5459792
doi: 10.1212/NXI.0000000000000360
Stuve O, Soelberg Soerensen P, Leist T, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12:1756286419854986.
pubmed: 31244898
pmcid: 6582297
doi: 10.1177/1756286419854986
Ruck T, Barman S, Schulte-Mecklenbeck A, et al. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain. 2022;145:1711–25.
pubmed: 35661859
pmcid: 9166548
doi: 10.1093/brain/awac064
Killestein J, van Oosten B. Emerging safety issues in alemtuzumab-treated MS patients. Mult Scler. 2019;25:1206–8.
pubmed: 31368417
pmcid: 6681426
doi: 10.1177/1352458519851219
Gross CC, Ahmetspahic D, Ruck T, et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3: e289.
pubmed: 27766281
pmcid: 5063395
doi: 10.1212/NXI.0000000000000289
Vermersch P, Gavin Giovannoni G, Soelberg Sørensen P, et al. Reduction of risk of secondary progressive multiple sclerosis within two years of treatment with cladribine tablets: an analysis of the CLARITY study. Mult Scler Relat Disord. 2020;37: 101602.
doi: 10.1016/j.msard.2019.11.077
Ceronie B, Jacobs BM, Baker D, et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J Neurol. 2018;265:1199–209.
pubmed: 29550884
pmcid: 5937883
doi: 10.1007/s00415-018-8830-y
Nath A, Berger JR. Complications of immunosuppressive/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol. 2012;14:241–55.
pubmed: 22528294
pmcid: 4910875
doi: 10.1007/s11940-012-0172-y
Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and Immunotherapy. Neuron. 2018;97:742–68.
pubmed: 29470968
doi: 10.1016/j.neuron.2018.01.021
Moser T, Ziemssen T, Sellner J. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr. 2022;172:1–8.
doi: 10.1007/s10354-022-00931-4
Hunter SF, Aburashed RA, Alroughani R, et al. Confirmed 6-month disability improvement and worsening correlate with long-term disability outcomes in alemtuzumab-treated patients with multiple sclerosis: post hoc analysis of the CARE-MS studies. Neurol Ther. 2021;10:803–18.
pubmed: 34165694
pmcid: 8571457
doi: 10.1007/s40120-021-00262-3
Giovannoni G, Cohen JA, Coles AJ, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016;87:1985–92.
pubmed: 27733571
pmcid: 5109953
doi: 10.1212/WNL.0000000000003319
Brod SA. In MS: immunosuppression is passé. Mult Scler Relat Disord. 2020;40: 101967.
pubmed: 32007655
doi: 10.1016/j.msard.2020.101967
Melamed E, Lee MW. Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies. Front Immunol. 2020;10:2954.
pubmed: 31998289
pmcid: 6965059
doi: 10.3389/fimmu.2019.02954
Giovannoni G, Singer BA, Issard D, Jack D, Vermersch P. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler. 2022;28:1219–28.
pubmed: 34634968
doi: 10.1177/13524585211049392
Brecl Jakob G, Barun B, Gomezelj S, et al. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study. Neurol Sci. 2021;42:4591–7.
pubmed: 33660157
doi: 10.1007/s10072-021-05145-x
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.
pubmed: 20089960
doi: 10.1056/NEJMoa0902533
Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.
pubmed: 23122652
doi: 10.1016/S0140-6736(12)61769-3
Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.
pubmed: 23122650
doi: 10.1016/S0140-6736(12)61768-1
Al Jumah M, Al Malik Y, AlKhawajah NM, et al. Family planning for people with multiple sclerosis in Saudi Arabia: an expert consensus. Mult Scler Int. 2021;2021:6667006.
pubmed: 33628508
pmcid: 7899766
Alroughani R, Inshasi J, Al-Asmi A, et al. Disease-modifying drugs and family planning in people with multiple sclerosis: a consensus narrative review from the Gulf Region. Neurol Ther. 2020;9:265–80.
pubmed: 32564333
pmcid: 7606397
doi: 10.1007/s40120-020-00201-8
Vermersch P, Oh J, Cascione M, et al. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Mult Scler Relat Disord. 2020;43: 102158.
pubmed: 32470857
doi: 10.1016/j.msard.2020.102158
D’Amico E, Zanghì A, Avolio C. Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies. Neural Regen Res. 2022;17:567–8.
pubmed: 34380893
doi: 10.4103/1673-5374.320985
Coyle PK, Khatri B, Edwards KR, et al. Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107–15.
pubmed: 29055438
doi: 10.1016/j.msard.2017.07.006
Inshasi JS, Alfahad S, Alsaadi T, et al. Position of cladribine tablets in the management of relapsing-remitting multiple sclerosis: an expert narrative review from the United Arab Emirates. Neurol Ther. 2021;10:435–54.
pubmed: 33891277
pmcid: 8062252
doi: 10.1007/s40120-021-00243-6
AlJumah M, Alkhawajah MM, Qureshi S, et al. Cladribine tablets and relapsing-remitting multiple sclerosis: a pragmatic, narrative review of what physicians need to know. Neurol Ther. 2020;9:11–23.
pubmed: 32056129
pmcid: 7229040
doi: 10.1007/s40120-020-00177-5
Horáková D, Boster A, Bertolotto A, et al. Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Mult Scler J Exp Transl Clin. 2020;6:2055217320972137.
pubmed: 33414927
pmcid: 7750777
Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344:9–13.
pubmed: 7912347
doi: 10.1016/S0140-6736(94)91046-4
Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999;18:53–63.
pubmed: 10023128
doi: 10.1159/000069408
Berkovich R. Effects of alemtuzumab on disability and cognition in patients with secondary progressive multiple sclerosis (SPMS). Neurology. 2017;88(16 Suppl):P5-356.
von Niederhäusern V, Ruder J, Ghraichy M, et al. B cell reconstitution after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9: e200027.
doi: 10.1212/NXI.0000000000200027
Willison AG, Ruck T, Lenz G, Hartung HP, Meuth SG. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J Neurol. 2022;269:3937–58.
pubmed: 35399125
pmcid: 8995166
doi: 10.1007/s00415-022-11063-5
Nabizadeh F, Pirahesh K, Rafiei N, et al. Autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. Neurol Ther. 2022;11:1553–69.
pubmed: 35902484
pmcid: 9333355
doi: 10.1007/s40120-022-00389-x
Kvistad SAS, Burman J, Lehmann AK, et al. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. J Neurol Neurosurg Psychiatry. 2022;93:844–8.
pubmed: 35508373
doi: 10.1136/jnnp-2022-328797
Kalincik T, Sharman S, Roos I, et al. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS. Abstract 0019 at the 2022 meeting of ECTRIMS, Amsterdam, Netherlands, 26–28 October 2022. https://ectrims2022.abstractserver.com/program/#/details/presentations/1018 . Accessed Nov 2022.
Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis. Neurology. 2021;96:e1574–84.
pubmed: 33514645
pmcid: 8032381
doi: 10.1212/WNL.0000000000011545
Das J, Sharrack B, Snowden JA. Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. Expert Rev Neurother. 2020;20:1299–313.
pubmed: 32893698
doi: 10.1080/14737175.2020.1820325
European Medicines Agency. Lemtrada. Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada . Accessed Aug 2022.
Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11:116–29.
pubmed: 34322364
pmcid: 8299905
doi: 10.5662/wjm.v11.i4.116